By far the biggest opportunity for SeerPharma in India's life sciences industry seems to be in the training sector. A significant amount of interest in the various training programs offered by SeerPharma in compliance and GXP, including validation, risk management and annual product reviews, was shown by individual companies, educational institutions and industry associations. We are hopeful that further discussions will enable SeerPharma to develop a relationship that will allow us to develop and deliver programs across the life sciences sector in India.

What are your views on the life sciences industry in India?

Mr Roberts: The life sciences industry in India, in particular pharmaceuticals, is predicted to grow significantly over the next three years and expected to be ranked the eighth largest market in the world by 2015. This is a significant increase from a ranking of 15th in 2005. This growth, along with more than 20,000 manufacturers, offers a significant opportunity for SeerPharma to provide good manufacturing practices (GMP) training and compliance services to this expanding market.

Although SeerPharma has had some experience in India in the past, the involvement has been very little and mainly under the banner of the World Health Organization (WHO). The Victoria government's trade mission to India this year provided an ideal opportunity for SeerPharma to investigate market opportunities and understand some of the business dynamics in the country.

How will you approach to enter the Indian market?